Get the Stockscreener App
40.95
2.80%
-1.18
After Hours:
40.86
-0.09
-0.22%
Travere Therapeutics Inc stock is traded at $40.95, with a volume of 4.52M.
It is down -2.80% in the last 24 hours and up +47.30% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.
See More
Previous Close:
$42.13
Open:
$42.335
24h Volume:
4.52M
Relative Volume:
2.13
Market Cap:
$3.78B
Revenue:
$490.73M
Net Income/Loss:
$-50.26M
P/E Ratio:
-67.91
EPS:
-0.603
Net Cash Flow:
$-20.37M
1W Performance:
+29.26%
1M Performance:
+47.30%
6M Performance:
+52.51%
1Y Performance:
+174.65%
1-Day Range:
$40.40
$42.66
1-Week Range:
$28.29
$43.31
52-Week Range:
$13.88
$43.31
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
40.95 | 3.89B | 490.73M | -50.26M | -20.37M | -0.603 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Travere Therapeutics: Re-Rating Potential As Filspari Wins Full Approval (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics sees its composite rating rise to 97 - MSN
Travere (TVTX) Soars 37.2%: Is Further Upside Left in the Stock? - Yahoo Finance
Travere Therapeutics TVTX Stock 2026 Outlook: Buy Rating Holds After FDA Approval of FILSPARI for FSGS - International Business Times Australia
Travere Therapeutics (TVTX) Shares Surge 33% in Trading - GuruFocus
TVTX (NASDAQ) Form 144 shows proposed resale after PRSU vesting, brokered by Morgan Stanley - Stock Titan
TVTX (NASDAQ: TVTX) files Form 144 to resell 7,215 RSU shares - Stock Titan
Elizabeth Reed reports sales of TVTX common stock (NASDAQ: TVTX) in Form 144 - Stock Titan
TVTX (NASDAQ: TVTX) Form 144 lists RSU vesting and planned share sales - Stock Titan
Bouncing Back From Trial Failure, Travere Wins First FDA Approval in Rare Kidney Disease - MedCity News
Travere’s Filspari approved for rare kidney disease FSGS - BioWorld News
Travere Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
[144] Travere Therapeutics, Inc. SEC Filing - Stock Titan
Travere Therapeutics (TVTX) Surges 32.5% in Market Performance - GuruFocus
Affiliate proposes sale of 9,052 TVTX shares via Morgan Stanley (TVTX) - Stock Titan
37,500-share planned sale at TVTX (NASDAQ: TVTX) — insider notice - Stock Titan
Travere Therapeutics Stock Skyrockets On Highly Anticipated FDA Approval - Investor's Business Daily
32,750-share Option Exercise Filed by TVTX (NASDAQ: TVTX) - Stock Titan
Stifel raises Travere Therapeutics price target on Filspari approval - Investing.com
Stifel raises Travere Therapeutics price target on Filspari approval By Investing.com - Investing.com Australia
Sandra Calvin insider sale reported (NASDAQ: TVTX) — 4,333 shares sold - Stock Titan
TVTX Maintained by Citigroup -- Price Target Raised to $53.00 - GuruFocus
Travere Therapeutics (TVTX) Sees 43% Surge After FDA Approval - GuruFocus
TVTX Maintains Rating by Wedbush -- Price Target Raised to $44 - GuruFocus
TVTX Maintained by Canaccord Genuity -- Price Target Raised to $56 - GuruFocus
TVTX Stock Jumps As FDA Approval Fuels Bullish Momentum - StocksToTrade
Ligand (LGND) Partners with Travere on FDA Approval for Filspari - GuruFocus
Travere wins long-awaited approval for kidney disease drug - BioPharma Dive
Travere Therapeutics (TVTX) Stock Rockets 44% on Groundbreaking FSGS Treatment Approval - MEXC
TVTX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $47 - GuruFocus
TVTX Stock Jumps As FILSPARI Wins Full FDA Approval - timothysykes.com
Travere Therapeutics Hits New 1-Year High After Analyst Upgrade - National Today
TVTX Maintained by Guggenheim -- Price Target Raised to $54.00 - GuruFocus
HC Wainwright Reiterates Buy Rating for Travere Therapeutics - National Today
Travere Therapeutics stock hits 52-week high at 42.2 USD By Investing.com - Investing.com South Africa
Avanos Medical, Travere Therapeutics, Globalstar And Other Big Stocks Moving Higher On Tuesday - Benzinga
Travere Therapeutics stock hits 52-week high at 42.2 USD - Investing.com
Travere Therapeutics Stock Soars 33% After FDA Approves FILSPARI as First Drug for Rare Kidney Disease FSGS - International Business Times Australia
Travere’s Filspari wins landmark US approval - The Pharma Letter
TVTX Stock On Track To Hit Near 20-Year Highs After Filspari Becomes The Only Approved FSGS Treatment - Stocktwits
Wedbush Raises Price Target on Travere Therapeutics to $44 From $39, Keeps Outperform Rating - marketscreener.com
Cantor Fitzgerald reiterates Travere stock rating on FSGS approval By Investing.com - Investing.com Canada
Travere Therapeutics (TVTX) Stock Surges 44% After FDA Approves FILSPARI for Rare Kidney Disease - CoinCentral
Travere, Ligand win FDA label expansion for Filspari (TVTX) - Seeking Alpha
First approved FSGS drug gives Ligand a 9% sales royalty - Stock Titan
Travere Wins FDA Approval for FILSPARI in FSGS - TipRanks
FDA approves Travere Therapeutics’ Filspairi for expanded kidney disease use - Investing.com
FDA approves FILSPARI for FSGS in Travere (NASDAQ: TVTX) patients - Stock Titan
Travere Therapeutics Gets FDA Approval for Filspari - marketscreener.com
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):